Quick Answer
Larimar Therapeutics, Inc. reported Operating Income of -$172.50 million for fiscal year 2025.
Larimar Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$172.50M | -89.8% |
| 2024 | -$90.89M | -117.7% |
| 2023 | -$41.76M | -14.3% |
| 2022 | -$36.53M | +27.6% |
| 2021 | -$50.47M | -17.9% |
| 2020 | -$42.80M | -84.4% |
| 2019 | -$23.21M | +62.0% |
| 2018 | -$61.12M | -15.3% |
| 2017 | -$53.00M | +9.0% |
| 2016 | -$58.23M | +21.1% |
| 2015 | -$73.81M | -107.7% |
| 2014 | -$35.53M | -157.9% |
| 2013 | -$13.78M | +0.1% |
| 2012 | -$13.79M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$49.50M | -171.0% | -78.1% |
| June 30, 2025 | -$27.79M | -13.0% | +10.9% |
| March 31, 2025 | -$31.19M | -86.4% | -70.8% |
| September 30, 2024 | -$18.26M | -76.7% | +25.8% |
| June 30, 2024 | -$24.60M | -155.7% | -47.0% |
| March 31, 2024 | -$16.73M | -119.1% | -61.9% |
| September 30, 2023 | -$10.34M | -21.4% | -7.5% |
| June 30, 2023 | -$9.62M | -10.7% | -26.0% |
- Larimar Therapeutics, Inc. showed a decrease of -89.8% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Larimar Therapeutics, Inc.’s operating income has declined by 1150.8% (from -$13.79 million to -$172.50 million).
- The most recent figure is from Larimar Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: